Adrian Isaacs
@isaacs_adrian
Investigating frontotemporal dementia and motor neuron disease at the UK Dementia Research Institute and UCL Queen Square Institute of Neurology
Our open access opinion in @Brain1878 on the disappointing C9 ASO trials and next steps to deliver an effective treatment for C9ALS/FTD co-written with @AlexCammack @RubikaBalendra @UKDRI @UCLIoN academic.oup.com/brain/article/…
Excited to be presenting unpublished work at the Lipids in Brain Diseases Symposium @LipidsInBrain in September. Hoping to learn a lot and still time to register: ccb.lumc.nl/2nd-symposium-…
A day in the life of our superstar tech Yash! recorded for @DHSCgovuk instagram.com/p/C94qZg8oVkT/ @UKDRI @UCLBrainScience @in2scienceUK
A study led by @isaacs_adrian (UK DRI at @UCLIoN) reveals a protective response in cells to early changes in ALS & FTD🧠 The research provides important insight that could lead to new therapeutic avenues to treat FTD & ALS👉buff.ly/3V5EZHc
New knock-in #ALS/#FTD mice express less normal C9ORF72 along with repeat dipeptides. They feature a protective collagen response. @UCL ow.ly/U6cW50QOZ8l
Delighted to see our study led by @milioto_carmelo revealing a neuroprotective ECM signature in C9FTD/ALS published! Thanks to @mndassoc @UKDRI and many others! nature.com/articles/s4159…
Brilliant to see former lab member Emma Clayton blazing her own trail!
Happy @WomenScienceDay!!🥳 🎉 🙌 Don't miss our new feature with UK DRI Emerging Leader Dr Emma Clayton. In the piece, Dr Clayton discusses her career path, the importance of representation and her passion for public engagement👏 👉buff.ly/3OFgU6d #WomenInScience
We have a new @lifearc1 funded post-doc position to follow up this work, applications close Feb 6th: ucl.ac.uk/work-at-ucl/se…
After failure of ASO trials targeting C9orf72 sense repeats also targeting antisense repeats is now vital. Our new preprint shows a potential approach using CRISPR-CasRx @UKDRI @UCLIoN @AlexCammack biorxiv.org/content/10.110…
After failure of ASO trials targeting C9orf72 sense repeats also targeting antisense repeats is now vital. Our new preprint shows a potential approach using CRISPR-CasRx @UKDRI @UCLIoN @AlexCammack biorxiv.org/content/10.110…
.@isaacs_adrian shares his optimism for new dementia treatments. He & his team of researchers @UKDRI are studying the underlying causes of dementia that will one day lead to new treatments for people with diseases like Alzheimer’s. His vital work will help us change the ending.
We are pleased to announce that the Fourth UCL Queen Square Motor Neuron Disease Centre International Symposium (hybrid event) will take place on Friday 8th September 2023. To register for this exciting meeting - eventbrite.co.uk/e/658581473917